https://www.selleckchem.com/pr....oducts/almorexant-hc
Convalescent plasma (CP) is being used as a treatment option in hospitalized patients with COVID-19. Till date, there is conflicting evidence on efficacy of CP in reducing COVID-19 related mortality. To evaluate the effect of CP on 28-day mortality reduction in patients with COVID-19. We did a multi-centre, retrospective case control observational study from 1st May 2020 to 31st August 2020. A total of 1079 adult patients with moderate and severe COVID-19 requiring oxygen, were reviewed. Of these, 694 patients were admitted to IC
Like
Comment
Share
